This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Plasmepsin
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <StructureSection load='' size=' | + | <StructureSection load='' size='350' side='right' caption='Plasmepsin II complex with a potential antimalarial drug (PDB entry [[4cku]])' scene='44/441867/Cv/1'> |
== Function == | == Function == | ||
[[Plasmepsin]] (Plm) is a hemoglobin-degrading enzyme produced by the plasmodium parasite. It is an aspartic acid protease having 2 aspartic acid residues in the active site. Ten Plm isoforms are known which are named Plm I, II, etc and '''Histo-Aspartic Protease (HAP)'''. | [[Plasmepsin]] (Plm) is a hemoglobin-degrading enzyme produced by the plasmodium parasite. It is an aspartic acid protease having 2 aspartic acid residues in the active site. Ten Plm isoforms are known which are named Plm I, II, etc and '''Histo-Aspartic Protease (HAP)'''. | ||
| Line 32: | Line 32: | ||
**[[3f9q]] – PfPlm II (mutant)<br /> | **[[3f9q]] – PfPlm II (mutant)<br /> | ||
**[[2r9b]] – PfPlm II + peptide inhibitor<br /> | **[[2r9b]] – PfPlm II + peptide inhibitor<br /> | ||
| - | **[[1w6h]], [[2bju]], [[1lf2]], [[1lf3]], [[1lee]], [[2igx]], [[2igy]], [[4cku]], [[4y6m]], [[4z22]] – PfPlm II + inhibitor<br /> | + | **[[1w6h]], [[2bju]], [[1lf2]], [[1lf3]], [[1lee]], [[2igx]], [[2igy]], [[4cku]], [[4y6m]], [[4z22]], [[5yia]], [[5yib]], [[5yic]], [[5yid]], [[5yie]] – PfPlm II + inhibitor<br /> |
**[[4ya8]] – PfPlm II (mutant) + inhibitor<br /> | **[[4ya8]] – PfPlm II (mutant) + inhibitor<br /> | ||
**[[1w6i]], [[1xdh]], [[1xe5]], [[1xe6]], [[1me6]], [[1sme]] – PfPlm II + pepstatin derivative<br /> | **[[1w6i]], [[1xdh]], [[1xe5]], [[1xe6]], [[1me6]], [[1sme]] – PfPlm II + pepstatin derivative<br /> | ||
| Line 41: | Line 41: | ||
**[[2anl]] – Plm IV + statine derivative – ''Plasmodium malariae''<br /> | **[[2anl]] – Plm IV + statine derivative – ''Plasmodium malariae''<br /> | ||
**[[1ls5]] - PfPlm IV + pepstatin derivative<br /> | **[[1ls5]] - PfPlm IV + pepstatin derivative<br /> | ||
| + | |||
| + | *Plasmepsin V | ||
| + | |||
| + | **[[6c4g]] – PvPlm V + inhibitor<br /> | ||
*Proplasmepsin II | *Proplasmepsin II | ||
| Line 46: | Line 50: | ||
**[[1pfz]], [[5bwy]] - PfProPlm II<br /> | **[[1pfz]], [[5bwy]] - PfProPlm II<br /> | ||
**[[1miq]] – PvProPlm II – ''Plasmodium vivax''<br /> | **[[1miq]] – PvProPlm II – ''Plasmodium vivax''<br /> | ||
| - | **[[1qs8]], [[5i70]] - PvPlm | + | **[[1qs8]], [[5i70]] - PvPlm II + pepstatin derivative<br /> |
}} | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 07:43, 22 August 2018
| |||||||||||
3D structures of plasmepsin
Updated on 22-August-2018
References
- ↑ Bernstein NK, Cherney MM, Loetscher H, Ridley RG, James MN. Crystal structure of the novel aspartic proteinase zymogen proplasmepsin II from plasmodium falciparum. Nat Struct Biol. 1999 Jan;6(1):32-7. PMID:9886289 doi:10.1038/4905
- ↑ Huizing AP, Mondal M, Hirsch AK. Fighting malaria: structure-guided discovery of nonpeptidomimetic plasmepsin inhibitors. J Med Chem. 2015 Jul 9;58(13):5151-63. doi: 10.1021/jm5014133. Epub 2015 Mar 17. PMID:25719272 doi:http://dx.doi.org/10.1021/jm5014133
- ↑ Jaudzems K, Tars K, Maurops G, Ivdra N, Otikovs M, Leitans J, Kanepe-Lapsa I, Domraceva I, Mutule I, Trapencieris P, Blackman MJ, Jirgensons A. Plasmepsin inhibitory activity and structure-guided optimization of a potent hydroxyethylamine-based antimalarial hit. ACS Med Chem Lett. 2014 Jan 13;5(4):373-7. doi: 10.1021/ml4004952. eCollection, 2014 Apr 10. PMID:24900843 doi:http://dx.doi.org/10.1021/ml4004952
Proteopedia Page Contributors and Editors (what is this?)
Michal Harel, Alexander Berchansky, Joel L. Sussman, Jaime Prilusky
